Just reported in formal 8k filing by PURE:
The owner of Subway, the largest food chain in the world, through Franchise Brands, LLC, just invested $4million in PURE Bioscience as a strategic investment. This strongly implies that some very large restaurant chains will soon start buying “SDC” in very large quantities. Do you think it might be the 45,000 restaurant Subway?
Several other major QSR’s are likely to follow soon.
PURE is very STRONG BUY because they have almost $8 million in cash, the biggest breakthrough in food safety in decades using biotechnology, and revenues that are about to explode.
Sentiment: Strong Buy
Type “MicroCapReview” into your browser to learn why Millennium HealthCare (MHCC) stock price is about to explode and keep going for years. Click on “Read the latest issue and turn to page 22.
Sentiment: Strong Buy
Thanks tmcg1367, that was quite an insight. I read similar sentiments on DXCM so just on the fence on to dump or keep it. I'll keep it till year end to see how it flows. I am sure a lot more news will be coming out on them.
I am thinking JNJ may purchase Dexcom.
Historically JNJ will work with a partner only to purchase them at a later date.
JNJ / Animas is working with Dexcom currently.
Continous monitoring eliminates the need for strips and eliminates the pain of lancing skin up to 7 times per day.
Conventional glucose monitors that require costly strips and lancing device will be replaced by Continous meters in the future.
I take an educated guess and would expect Dexcom has the potential to sell in the triple digits.
From Forbes: The business of glucose monitoring is growing at a fast rate of 25% annually, and experts estimate that by 2017, the market will exceed $30 billion worldwide
• JNJ acquired Inverness Medical Technology's Diabetes Care Products Business in $1.3 Billion Stock-for-Stock Transaction.
• JNJ purchased Animas Corp with a cash-for-stock agreement, worth approximately $518 million.
• JNJ purchased privately held Lifescan 1986.
There is a chance that, one day, this company will be taken over. It will also pop when J&J gets the OK on the Animus/Dexcom artificial pancreas which is before the FDA. The future will probably bring respectable increases in quarter by quarter sales and their first profitable quarter; they are already cash flow positive. They dominate the CGM market, so I don't think competition is a worry. They have just scratched the surface of foreign sales. These are the positives.
All of the above should increase the price, but from what base? If the market corrects, so will the price of DXCM. Also, insiders have been dumping shares like crazy, check it out.
If you are willing to hold for the long term you should do well. The call is yours, good luck.
Will this stk go more towards $70s or into triple digits? Any and all help will be greatly appreciated. I am holding my $49 buy price just to break even so wanted to know if I should hold it longer?
Up another 2% today.
After Cramer gives Dexcom a "buy, buy, buy" tonight I would expect price and volume to be up Monday morning.
This will be the 2nd time Terry's been on MM in the past few months. Plus his two appearances on Fast Money within the past 6 months or so. Dexcom is clearly the bell of the ball lately and with good reason. They're earnings call the other day was great. The sky's the limit for DXCM.
Sentiment: Strong Buy
Not all of their posts are fake. I posted a complimentary post a few weeks ago and these jerks have reposted my post under different names several times. The funny thing is, I complained about the huge amount of spam on this board and they used that comment also.
I checked them out as I've seen your suggestion on pretty much every stock board there is it seems. It is really a horrible product. Don't know why anyone would waste there time with it. So bad in my humble opinion.
Upbeat call, not only in terms of impressive second quarter financial results, and in the raising of estimates for this calendar year, but in the optimism and enthusiasm from management's presentation. Analysts obviously were impressed with the quarter and the prospects for a better than expected 2014 as a whole. Optimism regarding prospects for increasing sales later this year from further penetration of the pediatric population, increasing margins from recurring use of disposables as new patients start using Dexcom CGM regularly, and the incremental international growth and the potential for further growth in the US once the Animus Vibe pump gets approval in the next few months via the marketing muscle of JNJ. Finally the optimism around the possibility of medicare coverage for CGM via congressional legislation or new clinical data persuading CMS to allow coverage of CMG as a necessary part of treatment for Type 1 DM in the medicare population, and the progress being made in using Dexcom sensors in recently presented bionic pancreas research at the ADA meetings makes the future of this company very bright. I expect upgrades and higher price targets tomorrow.
As Dexcom meter sales increase so will the reoccurring revenue stream.
The disposables are where profits are generated or at least it is for a conventional glucose meter and strip industry.
A glucose strip can be manufactured for as little #$%$ cents but sells for 75 cents.
This is why glucose monitors are sold at cost or given to diabetics for free.
Not sure what the kind of profit is generated from Dexcom’s disposable but I assume it is comparable to conventional monitors.
This is fantastic: this sort of analysis is exactly what I’ve been looking at doing myself. Thank you and great work.